Journal: Head and Neck Pathology
Article Title: Comparison of Molecular Methods and BRAF Immunohistochemistry (VE1 Clone) for the Detection of BRAF V600E Mutation in Papillary Thyroid Carcinoma: A Meta-Analysis
doi: 10.1007/s12105-020-01166-8
Figure Lengend Snippet: Papillary thyroid carcinoma, classic type (a) showing diffuse cytoplasmic VE1 expression with moderate intensity (b); Papillary thyroid carcinoma, invasive follicular variant (c) showing negative VE1 immunostain (d). Evaluation of VE1 immunostain in papillary thyroid carcinoma at low power (e) may be deceptive. Higher power examination confirms diffuse but weak VE1 positivity (f) in a case with confirmed BRAF V600E mutation by next generation sequencing (unpublished data). These examples utilized prediluted Roche Ventana VE1 monoclonal antibody (Indianapolis, IN, USA) on the Leica Bond Refine System (Buffalo Grove, IL, USA) at 60 min incubation time
Article Snippet: The majority of the studies used the anti-human BRAF V600E (clone VE1) monoclonal antibody by Spring Bioscience (Spring Bioscience Pleasanton, CA, USA) [ 11 , 13 – 15 , 18 , 21 , 25 , 26 , 28 – 30 , 32 , 39 , 40 ] or Ventana medical systems (Ventana Medical Systems, Roche Diagnostics Indianapolis, IN, USA) [ 12 , 17 , 19 , 20 , 22 , 33 – 35 ].
Techniques: Expressing, Variant Assay, Mutagenesis, Next-Generation Sequencing, Incubation